Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage ABSTRACT Objective: To evaluate the safety and feasibility of percutaneous left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) and previous intracranial hemorrhage (ICH).
Oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and previous intracranial hemorrhage (ICH) is associated with an increased risk of recurrent ICH, and its use in this setting is therefore controversial. 1 Left atrial appendage occlusion (LAAO) has a role in patients with thromboembolic risk who cannot be managed in the long term using any form of OAC. [2] [3] [4] Remarkably, however, the sole randomized trial of LAAO (PROTECT AF) included only patients eligible for warfarin treatment, excluding patients with previous ICH 5 ; no prospective data on this important patient population are available from registries. We hypothesize that percutaneous LAAO could be an alternative stroke prevention in these patient populations.
The purpose of our prospective study was to provide pilot data regarding the feasibility and safety of LAAO in patients with AF and previous ICH.
The medical history, basic demographic variables, NIH Stroke Scale, mRS, CHA 2 DS 2 Vasc score, and HAS-BLED score 6 were recorded. The day after the procedure and 1, 6, 12, and 24 months thereafter, clinical status and intermittent complications were documented.
In accordance with the PROTECT AF trial, 5 interventionrelated major complications were predefined as ischemic or hemorrhagic stroke, death, pericardial effusion, and device embolism. Inguinal pseudoaneurysm, arteriovenous fistula, hematoma, thrombus formation on the device, and minor bleeding (single or repeated) not requiring intervention were predefined as minor complications.
Left atrial appendage occlusion. LAAO was performed under transesophageal echocardiographic and fluoroscopic guidance. Access to the left atrium was obtained via the right femoral vein and subsequent transseptal puncture. To prevent clot formation, heparin was given IV after transseptal puncture. A sheath was inserted into the orifice of the left atrial appendage (LAA) and the occluder (Amplatzer Cardiac Plug [ACP]; St. Jude Medical, St. Paul, MN) was implanted into the LAA using a self-expanding nitinol frame.
After the procedure, antithrombotic treatment using combined antiplatelet medication (aspirin 100 mg/day and clopidogrel 75 mg/day) was given for 3 months, followed by aspirin monotherapy thereafter. Device position was verified by transesophageal echocardiogram (TEE) at 1 and 6 months after the procedure.
Standard protocol approvals, registrations, and patient consents. The local ethics committee approved all study procedures. Each patient provided written informed consent for study participation. Classification of evidence. This study aimed to obtain Class III evidence that in patients with a history of previous ICH and AF, percutaneous LAAO is safe and feasible.
RESULTS
The figure illustrates a flow diagram of the study population. A total of 24 patients with AF and previous ICH agreed to undergo LAAO. In 3 patients, TEE revealed that the LAA was too large for device placement, and in 1 patient a thrombus was detected in the LAA before the intervention (table 1) . Hence, LAAO was performed in 20 patients (table 1) .
Patient characteristics and baseline variables are shown in table 2. According to the mean CHA 2 DS 2-Vasc score (table 2), the estimated subsequent annual stroke risk was 4.0%-6.7%. Based on the mean HAS-BLED score, the annual bleeding risk was 8.7%-12.5% for major hemorrhage and 1.2%-1.6% for ICH. No patient had a periprocedural major complication. Four patients had a postprocedural minor complication (2 inguinal hematoma, 1 self-limiting asystole, 1 thrombus formation on the occluder). Device-associated thrombus resolved without ischemic complications after 2 months of OAC with rivaroxaban.
The clinical efficacy of LAAO was evaluated during a mean follow-up period of 13.6 6 8.2 months. No ischemic or hemorrhagic strokes and no TIAs were observed. Disability scores were unchanged at the follow-up visits (table 2) . DISCUSSION This pilot study of LAAO dedicated exclusively to patients with AF and previous ICH suggests that LAAO is feasible and safe in these patients.
While adverse events during long-term pharmacologic therapy with OAC usually develop continuously over time, interventions such as LAAO can cause early procedure-related events. 7 The only prospective randomized controlled trial (PROTECT AF) comparing the efficacy and safety of LAAO and warfarin in patients with AF 5 reported periprocedural complications in 7.4% of patients. The adverse events encompassed pericardial effusion (4.8%), periprocedural stroke (1.1%), and device embolism (0.6%). A subsequent study registry (CAP) also using the Watchman device documented substantially lower complication rates (pericardial effusion 2.2% and periprocedural stroke 0%). 7 Limited data obtained using the ACP device initially showed complication rates of 7.3%, 8 but the incidence of complications has decreased considerably with increasing experience of those performing the intervention. 7, 9 We observed no major and only 4 minor complications in our patients.
Patients with AF have an increased risk of hemorrhagic complications, particularly when under treatment with antithrombotics or anticoagulants. The HAS-BLED score was introduced to estimate the bleeding risk and it correlates with ICH risk. 10 The mean HAS-BLED score in our study is associated with an increased annual risk of major (8.7%-12.5%) and intracranial bleeding (1.2%-1.6%) under treatment of OAC. We observed no ICH or major systemic bleeding events during follow-up. These findings regarding periprocedural and hemorrhagic complications suggest that it is safe to perform LAAO in AF patients with previous ICH. Due to the limited number of patients and the study design, our data do not permit firm conclusions regarding the efficacy of the procedure. During a mean follow-up period of 13.6 6 8.2 months, however, no strokes or systemic embolism were noted in our study. Post hoc analysis of the PROTECT AF and CAP registry data showed the greatest net clinical benefit of LAAO in patients at a higher risk of stroke according to the CHADS 2 score and in patients with increased risk of bleeding. 9 The annual risk of stroke according to the CHA 2 DS 2 Vasc score in our study was at least twice as high as the annual stroke rates reported in previous LAAO studies (2.2% and 2.0%, respectively). 5, 7 New oral anticoagulants may help to prevent stroke in AF patients with previous ICH, because they have been consistently associated with a lower risk of ICH complications than warfarin. 3, 4 Moreover, the AVERROES trial reported no excess risk of major bleeding in AF patients treated with apixaban compared to aspirin. 3 However, no data are yet available for new oral anticoagulants in patients with previous ICH.
Our study has strengths and limitations. It was prospective, patient enrollment was consecutive, and the patients were followed up for 2 years. The major limitations of the study are performance at a single center and the small number of patients, meaning that it lacks adequate power for robust conclusions regarding safety and efficacy. We therefore caution against uncritical alteration of routine clinical practice on the basis of our data. Moreover, our cohort encompassed heterogeneous subtypes with different latencies since the index ICH and differing risks of recurrent ICH. This pilot study of LAAO in patients with AF and previous ICH suggests that LAAO may be an alternative to oral anticoagulation for stroke prevention in these patients. Further evaluation of the efficacy and safety of LAAO in large prospective, controlled trials is necessary to evaluate the value of the procedure. 
